BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 594.50% and ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.

In light of Eli Lilly's impressive financial performance, strategic expansion, and strong analyst endorsements, the company seems poised for continued growth. Even with its stock trading near all-time ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

Eli Lilly And Co (NYSE:MRK) revealed new long-term results on Wednesday, showing promise for treatment in patients with ...

Minnesota clinics are starting to receive free or low-cost insulin from Eli Lilly and Sanofi. This comes after the Minnesota ...